A Phase 3 interventional study of polymyxin B sulphate + prednisolone + benzocaine + clioquinol and betamethasone + gentamicin + tolnaftato + cleoquinol in Eczema, sponsored by EMS. Completed. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-02-24.
Sponsored by EMS · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Dermatitis eczematous is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The purpose of this trial is evaluate the effectiveness of two different topic associations of drugs.
Study design:
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
This study's enrollment of 76 is below the median of 91 across 403 interventional studies indexed under Eczema.
Browse Eczema studies →EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
polymyxin B sulphate + prednisolone + benzocaine + clioquinol
Drug: polymyxin B sulphate + prednisolone + benzocaine + clioquinol
betamethasone + gentamicin + tolnaftato + clioquinol
Drug: betamethasone + gentamicin + tolnaftato + cleoquinol
Drug pages: Polymyxin B · Prednisolone · Benzocaine · Clioquinol
applied 3 times / day at lesion
applied 3 times / day at lesion
Reduction / improvement of signs and symptoms
The reduction of signs and symptoms will be evaluated by OSAAD index.
Time frame: DAY 22
Adverse Events Evaluation
Adverse events will be collected and followed in order to evaluate safety and tolerability.
Time frame: DAY 22
No study locations are listed for this record.
The record gives a start of May 2012, a primary completion of Jun 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Polymyxin B · Prednisolone · Benzocaine · Clioquinol